Pacific Biosciences Of California (PACB) Return on Capital Employed (2011 - 2026)

Pacific Biosciences Of California's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 18.57% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 6412.0% year-over-year to 18.57% in Q1 2026; TTM through Mar 2026 was 18.57%, a 6412.0% increase from a year earlier, with the FY2025 full-year figure at 58.34%, down 2533.0% from the prior year.
• Return on Capital Employed rose to 18.57% in Q1 2026 per PACB's latest filing, from 76.84% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 11.17% in Q1 2022 and bottomed at 88.63% in Q3 2025.
• The 5-year median for Return on Capital Employed is 20.38% (2023), against an average of 35.86%.
• Across the five-year window, Return on Capital Employed slumped 6283 bps in 2025 and soared 6412 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 20.08% in 2022, then climbed by 4 bps to 19.37% in 2023, then sank by 90 bps to 36.8% in 2024, then plunged by 109 bps to 76.84% in 2025, then soared by 76 bps to 18.57% in 2026.
• Per Business Quant, the three latest PACB Return on Capital Employed figures stand at 18.57% (Q1 2026), 76.84% (Q4 2025), and 88.63% (Q3 2025).